STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
30
01
2022
accepted:
15
06
2022
revised:
22
07
2022
pubmed:
2
7
2022
medline:
27
7
2022
entrez:
1
7
2022
Statut:
epublish
Résumé
Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma (KS)-associated herpesvirus, is involved etiologically in AIDS-associated KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease, in which both viral latent and lytic functions are important. HHV-8 encodes four viral interferon regulatory factors (vIRFs) that are believed to contribute to viral latency (in PEL cells, at least) and/or to productive replication via suppression of cellular antiviral and stress signaling. Here, we identify vIRF-1 interactions with signal transducer and activator of transcription (STAT) factors 1 and 2, interferon (IFN)-stimulated gene factor 3 (ISGF3) cofactor IRF9, and associated signal transducing Janus kinases JAK1 and TYK2. In naturally infected PEL cells and in iSLK epithelial cells infected experimentally with genetically engineered HHV-8, vIRF-1 depletion or ablation, respectively, led to increased levels of active (phosphorylated) STAT1 and STAT2 in IFNβ-treated, and untreated, cells during lytic replication and to associated cellular-gene induction. In transfected 293T cells, used for mechanistic studies, suppression by vIRF-1 of IFNβ-induced phospho-STAT1 (pSTAT1) was found to be highly dependent on STAT2, indicating vIRF-1-mediated inhibition and/or dissociation of ISGF3-complexing, resulting in susceptibility of pSTAT1 to inactivating dephosphorylation. Indeed, coprecipitation experiments involving targeted precipitation of ISGF3 components identified suppression of mutual interactions by vIRF-1. In contrast, suppression of IFNβ-induced pSTAT2 was effected by regulation of STAT2 activation, likely via detected inhibition of TYK2 and its interactions with STAT2 and IFN type-I receptor (IFNAR). Our identified vIRF-1 interactions with IFN-signaling mediators STATs 1 and 2, co-interacting ISGF3 component IRF9, and STAT-activating TYK2 and the suppression of IFN signaling via ISGF3, TYK2-STAT2 and TYK2-IFNAR disruption and TYK2 inhibition represent novel mechanisms of vIRF function and HHV-8 evasion from host-cell defenses.
Identifiants
pubmed: 35776779
doi: 10.1371/journal.ppat.1010676
pii: PPATHOGENS-D-22-00189
pmc: PMC9307175
doi:
Substances chimiques
Interferon Regulatory Factors
0
Interferon Type I
0
STAT1 Transcription Factor
0
STAT2 Transcription Factor
0
Janus Kinases
EC 2.7.10.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010676Subventions
Organisme : NIAID NIH HHS
ID : R01 AI140855
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Virol. 2000 Apr;74(7):3388-98
pubmed: 10708456
Science. 1996 Dec 6;274(5293):1739-44
pubmed: 8939871
Mol Cell. 2015 Jan 22;57(2):349-60
pubmed: 25544563
Blood. 2008 Jan 1;111(1):320-7
pubmed: 17890449
PLoS Pathog. 2010 Aug 05;6(8):e1001031
pubmed: 20700448
J Biol Chem. 2016 Mar 18;291(12):6281-91
pubmed: 26786098
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3840-5
pubmed: 16497831
J Virol. 2018 Mar 14;92(7):
pubmed: 29343584
J Virol. 2004 Jun;78(12):6621-35
pubmed: 15163753
EMBO J. 2013 Oct 16;32(20):2751-63
pubmed: 24065129
J Virol. 2009 May;83(10):5056-66
pubmed: 19279093
Genes Dev. 2006 Dec 15;20(24):3372-81
pubmed: 17182865
Biochem J. 2015 Mar 15;466(3):511-24
pubmed: 25564224
Nat Rev Immunol. 2012 Jan 06;12(2):125-35
pubmed: 22222875
Oncogene. 2001 Feb 15;20(7):800-11
pubmed: 11314014
J Virol. 2021 Apr 12;95(9):
pubmed: 33597212
J Biol Chem. 2019 Jun 14;294(24):9503-9517
pubmed: 31040183
Nat Struct Mol Biol. 2011 Nov 06;18(12):1336-44
pubmed: 22056774
J Virol Methods. 2011 Jun;174(1-2):12-21
pubmed: 21419799
Cytokine. 2010 Apr;50(1):1-14
pubmed: 20036577
J Virol. 2015 Oct 28;90(1):506-20
pubmed: 26512076
Cancer Res. 2009 Apr 15;69(8):3673-80
pubmed: 19351818
Virology. 2017 Jul;507:161-169
pubmed: 28441586
J Virol. 2020 Jan 6;94(2):
pubmed: 31666375
J Biol Chem. 1997 Feb 14;272(7):4600-5
pubmed: 9020188
J Biol Chem. 1997 Aug 8;272(32):20070-6
pubmed: 9242679
Mol Cell Biol. 2000 Nov;20(21):8254-63
pubmed: 11027294
J Virol. 2003 Jul;77(13):7635-44
pubmed: 12805463
J Gen Virol. 2011 Oct;92(Pt 10):2394-2398
pubmed: 21697347
J Gen Virol. 2003 Jun;84(Pt 6):1471-1483
pubmed: 12771416
Oncogene. 1997 Oct 16;15(16):1979-85
pubmed: 9365244
J Virol. 1998 Jul;72(7):5433-40
pubmed: 9620998
Cytotechnology. 2010 Jan;62(1):73-82
pubmed: 20309632
J Virol. 2015 Apr;89(8):4227-36
pubmed: 25631085
J Virol. 2008 Nov;82(21):10444-54
pubmed: 18701593
J Virol. 2012 Mar;86(5):2769-79
pubmed: 22171275
J Virol. 2017 Apr 28;91(10):
pubmed: 28250121
Sci Rep. 2019 Mar 20;9(1):4902
pubmed: 30894629
PLoS Pathog. 2019 May 6;15(5):e1007743
pubmed: 31059555
J Virol. 2002 Sep;76(17):8797-807
pubmed: 12163600
J Biol Chem. 2004 Sep 17;279(38):39199-206
pubmed: 15175343
J Virol. 2003 Apr;77(7):4205-20
pubmed: 12634378
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8369-74
pubmed: 20404187
J Virol. 2013 Dec;87(24):13676-93
pubmed: 24109218
J Virol. 2017 Oct 27;91(22):
pubmed: 28878084
Biol Chem. 2017 Jul 26;398(8):857-870
pubmed: 28455950
J Virol. 2015 Aug;89(15):7979-90
pubmed: 26018151
Nat Microbiol. 2019 Jun;4(6):914-924
pubmed: 30936491
J Virol. 1999 Apr;73(4):3040-53
pubmed: 10074154
J Exp Med. 2005 May 16;201(10):1543-53
pubmed: 15883169
J Virol. 2013 Sep;87(17):9398-410
pubmed: 23785197
EMBO J. 2003 Feb 3;22(3):537-47
pubmed: 12554654
J Interferon Cytokine Res. 1997 Mar;17(3):121-34
pubmed: 9085936
Cytokine Growth Factor Rev. 2016 Jun;29:35-43
pubmed: 26987614
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4306-15
pubmed: 26199418
J Virol. 1999 Sep;73(9):7334-42
pubmed: 10438822
PLoS Pathog. 2012;8(6):e1002748
pubmed: 22685405
Cancer Res. 2005 Mar 1;65(5):1738-47
pubmed: 15753369
Virology. 2020 Feb;541:160-173
pubmed: 32056714